Australia markets closed

Kuros Biosciences AG (CSBTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
6.65+0.40 (+6.40%)
As of 09:30AM EDT. Market open.

Kuros Biosciences AG

Wagistrasse 25
Schlieren 8952
Switzerland
41 44 733 4747
https://www.kuros.ch

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees80

Key executives

NameTitlePayExercisedYear born
Mr. Christopher T. FairChief Executive Officer576.7kN/A1970
Mr. Daniel GeigerChief Financial OfficerN/AN/A1971
Mr. Sjoerd MustersCOO & GM of BVN/AN/A1980
Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D.President of Innovation and Strategy & Executive Director633.57kN/A1966
Dr. Philippe Saudan Ph.D.Chief Development OfficerN/AN/A1967
Mr. John GriffinChief Commercial OfficerN/AN/AN/A
Dr. Katherine Sage D.O., FAAOS, M.S.Senior Vice President of Medical and Clinical AffairsN/AN/AN/A
Dr. Virginia JamiesonConsultantN/AN/A1953
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Corporate governance

Kuros Biosciences AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.